Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 10;21:43. doi: 10.1186/s12943-022-01519-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — METTL7B was overexpressed in TKIs-resistant LUAD cells. a Bioinformatics analysis of the differential expression of METTL family between PC9 and PC9-GR cells from Gene Expression Omnibus (GEO) databases GSE74253. b and c qRT-PCR and immunoblot analysis on the expression of METTL7B in PC9, PC9-GR and PC9-OR cells. d The TKI-resistant PDX and CDX tumor models. e-l Patient-derived tumors were implanted into the flank of BALB/c nude mice to form subcutaneous tumors. The mice with subcutaneously implanted tumors were treated with gefitinib or osimertinib (30 mg/kg, qd, po). The tumor volumes were presented from five mice per group. At the end of experiment, the tumors were taken out and METTL7B mRNA and protein levels were evaluated. m-p The same experiments with (e-l) but in PC9 cell-derived xenograft tumors. Quantification of relative METTL7B mRNA levels from three independent experiments were shown. *P < 0.05, **P < 0.01, ***P < 0.001